Stay updated on Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe history now includes Revision: v3.4.3 and no longer displays Revision: v3.4.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedRevision history updated: added entry v3.4.2 and removed entry v3.4.1.SummaryDifference0.1%

- Check38 days agoChange DetectedA new revision v3.4.1 was added to the history, and revision v3.4.0 was removed.SummaryDifference0.1%

- Check52 days agoChange DetectedThe history page now includes a glossary toggle, color-coded change highlights (green for additions, red for deletions), and a revision label (v3.4.0).SummaryDifference1.0%

- Check59 days agoChange DetectedA new revision entry v3.3.4 was added to the Record History, and the previous entry v3.3.3 was removed. This update affects only metadata and does not alter study content, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check88 days agoChange DetectedA new Revision: v3.3.3 was added to the record history, and the HHS Vulnerability Disclosure and Revision: v3.3.2 entries were removed.SummaryDifference0.2%

Stay in the know with updates to Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page.